On 21 October 2021 Genovis AB (publ.) entered into a license agreement with Selecta Biocience/Carhtesian Therapeutics. This license agreement has now been terminated by Carthesian Therapeutics and all right to the unique Xork(TM) enzyme are returned to Genovis. This opens up for new business opportunities with other partners within gene therapy and autoimmune diseases.

Substantial resources have already been invested in the project, which now will be for the benefit of Genovis, amongst other items second and third generation of the Xork enzyme with corresponding patent applications. Currently there are no known pre-clinical or clinical data that suggest that there should not be future opportunities for therapeutic applications of Xork.